Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.47 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | ECE1 | P42892 | 1/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.35 |
| ▸ | MME | P08473 | 3/20 | 0.35 |
| ▸ | ACE | P12821 | 1/20 | 0.35 |
| ▸ | CPA1 | P15085 | 1/20 | 0.35 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29499687 | 0.98 | PTGS1 (0.46) | PTGS1GSTK1GLO1ALDH1A1LMNA | |
| SCHEMBL29671487 | 0.98 | PTGS1 (0.46) | PTGS1GSTK1GLO1ALDH1A1LMNA | |
| SCHEMBL30733592 | 0.94 | PTGS1 (0.46) | PTGS1GSTK1GLO1ALDH1A1LMNA | |
| SCHEMBL29671001 | 0.94 | PTGS1 (0.46) | PTGS1GSTK1GLO1ALDH1A1LMNA | |
| SCHEMBL30692039 | 0.92 | PTGS1 (0.48) | PTGS1GSTK1GLO1ALDH1A1LMNA | |
| SCHEMBL30037966 | 0.90 | PTGS1 (0.44) | PTGS1GSTK1GLO1ALDH1A1LMNA | |
| SCHEMBL29349734 | 0.90 | PTGS1 (0.44) | PTGS1GSTK1GLO1ALDH1A1LMNA | |
| SCHEMBL30666386 | 0.90 | PTGS1 (0.44) | PTGS1GSTK1GLO1ALDH1A1LMNA | |
| SCHEMBL30974035 | 0.89 | GLO1 (0.46) | PTGS1GSTK1GLO1 | |
| SCHEMBL29644351 | 0.89 | PDCD1LG2 (0.44) | PTGS1GSTK1GLO1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4415748-A1 | MULTIEPITOPE SELF-ASSEMBLED NANOPARTICLE VACCINE PLATFORM (MSN-VACCINE PLATFORM) AND USES THERE OF | Translational Health Science and Technology Institute (IN) | 2024-08-21 | — | — | EP | claimed |
| WO-2023062515-A1 | MULTIEPITOPE SELF-ASSEMBLED NANOPARTICLE VACCINE PLATFORM (MSN-VACCINE PLATFORM) AND USES THERE OF | TRANSLATIONAL HEALTH SCIENCE AND TECHNOLOGY INSTITUTE (IN) | 2023-04-20 | — | — | WO | claimed |
| EP-4731652-A1 | MULTI-SPECIFIC PROTEINACEOUS PRODRUG CONSTRUCTS | Aarhus Universitet (DK) | 2026-04-29 | — | — | EP | disclosed |
| US-12570708-B2 | Recombinant proteins and their therapeutic uses | IN3BIO LTD (BM) | 2026-03-10 | — | — | US | disclosed |
| EP-4608512-A2 | ANTI-CD3 ANTIBODIES | Ablexis, LLC (US) | 2025-09-03 | — | — | EP | disclosed |
| WO-2025049345-A1 | ANTI-IL-13 MULTISPECIFIC ANTIBODY CONSTRUCTS AND USES THEREOF | PROTEOLOGIX US INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| US-20250066439-A1 | RECOMBINANT PROTEINS AND THEIR THERAPEUTIC USES | IN3BIO LTD. (BM) | 2025-02-27 | — | — | US | disclosed |
| WO-2024261212-A1 | MULTI-SPECIFIC PROTEINACEOUS PRODRUG CONSTRUCTS | AARHUS UNIVERSITET (DK) | 2024-12-26 | — | — | WO | disclosed |
| EP-4473007-A1 | A BIOPHARMACEUTICAL PRODRUG PLATFORM BASED ON PROTEIN CONFORMATIONAL CHANGE | Aarhus Universitet (DK) | 2024-12-11 | — | — | EP | disclosed |
| CN-119080874-A | O-tert-butyl-L-seryl-glycine and preparation method thereof | 四川什邡市三高生化实业有限公司 | 2024-12-06 | — | — | CN | disclosed |
| US-20240374745-A1 | BIOPHARMACEUTICAL PRODRUG PLATFORM BASED ON PROTEIN CONFORMATIONAL CHANGE | AARHUS UNIVERSITET (DK) | 2024-11-14 | — | — | US | disclosed |
| CN-116096754-A | Precursor trispecific antibody constructs and methods of use thereof | 免疫里森公司 | 2023-05-09 | — | — | CN | disclosed |
| WO-2023285489-A1 | OVERCOMING ANTIBODY-INTERFERENCE IN AVIANS | INTERVET INTERNATIONAL B.V. (NL) | 2023-01-19 | — | — | WO | disclosed |
| CN-115521374-A | Conditionally active polypeptides | 生物蛋白有限公司 | 2022-12-27 | — | — | CN | disclosed |
| CN-110072890-B | Activatable anti-CTLA-4 antibodies and uses thereof | 百时美施贵宝公司 | 2022-11-29 | — | — | CN | disclosed |
| CN-108473555-B | Conditionally active polypeptides | 生物蛋白有限公司 | 2022-10-25 | — | — | CN | disclosed |
| CN-115181173-A | Preparation method of Tirzepatide | 深圳市健元医药科技有限公司 | 2022-10-14 | — | — | CN | disclosed |
| US-20220315909-A1 | PROTEASE SUBSTRATE, AND POLYPEPTIDE INCLUDING PROTEASE CLEAVAGE SEQUENCE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-10-06 | — | — | US | disclosed |
| WO-2022138692-A1 | ANTIGEN-BINDING MOLECULES WITH IMPROVED CYTOSOL-PENETRATING ACTIVITY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-06-30 | — | — | WO | disclosed |
| US-20220153798-A1 | RECOMBINANT PROTEINS AND THEIR THERAPEUTIC USES | IN3BIO LTD. (BM) | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570708-B2 | Recombinant proteins and their therapeutic uses | EGFR, CALCB, ANTXR2 | PTGS1 3461/4885GSTK1 4642/4885GLO1 4747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.